



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2014

(Rs. in Lacs except for share data)

PART I		Quarter Ended			Financial Year Ended	
Sr. No.	Particulars	31st Mar 2014	31st Dec 2013	31st Mar 2013	31st Mar, 2014	31st Mar, 2013
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Income from Operations					
	(a) Gross Sales / Income from Operations	30,386	23,895	23,647	104,436	88,575
	Less : Excise Duty & Sales Tax	2,207	1,719	1,629	7,441	6,091
	(ii) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	28,179	22,176	22,018	96,994	82,484
	(b) Other Operating Income	125	40	18	183	91
	Total income from operations (net)	28,304	22,215	22,035	97,176	82,575
2	Expenditure					
	(a) Cost of materials consumed	15,667	11,874	12,722	57,082	49,244
	(b) Purchase of stock-in-trade	1,758	1,800	2,057	8,602	8,543
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,383	644	(188)	569	(2,259)
	(d) Employee benefits expense	852	806	762	3,241	2,853
	(e) Depreciation and Amortisation Expense	759	699	672	2,812	2,598
	(f) Other expenses	3,266	3,347	3,160	13,046	12,161
	Total expenses	24,793	19,170	19,185	85,351	73,140
3	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	3,511	3,045	2,850	11,825	9,435
4	Other income					
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	3,511	3,045	2,850	11,825	9,435
6	Finance costs (Interest)	917	924	756	3,349	2,804
7	Profit from ordinary activities after finance cost but before Exceptional items (5-6)	2,595	2,121	2,085	8,476	6,631
8	Exceptional items					
9	Profit from Ordinary Activities before Tax (7-8)	2,595	2,121	2,085	8,476	6,631
10	Tax Expenses					
	Provision for Taxation - Current	399	705	670	2,397	2,064
	- Earlier year	630	615	590	2,300	1,760
	Provision for Deferred Taxation	(321)	-	-	(253)	
		80	90	80	350	304
11	Net profit from ordinary Activities after Tax (9-10)	2,195	1,416	1,425	6,080	4,567
12	Extraordinary items					
13	Net Profit for the Period (11+12)	2,195	1,416	1,381	6,171	4,524
12	Paid-up Equity Share Capital of Rs.10/- each.	1,211	1,211	1,211	1,211	1,211
13	Reserves & Surplus (excluding revaluation reserves)				23,880	19,550
14	Earning per share (of Rs. 10 /- each) (not annualised)					
	(a) Basic & Diluted (before extraordinary items)	18.13	11.69	11.76	60.21	37.72
	(b) Basic & Diluted (after extraordinary items)			11.40	50.97	37.36

PART II

PART II		Quarter Ended			Financial Year Ended	
Sr. No.	Particulars	31st Mar 2014	31st Dec 2013	31st Mar 2013	31st Mar, 2014	31st Mar, 2013
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	-Number of Shares	4,890,428	4,901,063	5,154,122	4,890,428	5,154,122
	-Percentage of Total Shareholding	40.39	40.48	42.57	40.39	42.57
2	Promoters & Promoter Group shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered					
	- Number of Shares	7,218,122	7,207,497	6,954,428	7,218,122	6,954,428
	-Percentage of shares(as a % of the total Shareholding of promoter and promoter group)	100	100	100	100	100
	-Percentage of shares(as a % of the total Share capital of the company)	59.61	59.52	57.43	59.61	57.43



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433


	Qtr Ended 31st Mar 2014
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	0
Received during the quarter	5
Disposed of during the quarter	5
Remaining unresolved at the end of the quarter	0

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2014 (Rs. in lacs)			
Particulars	For the year ended		
	31/03/2014	31/03/2013	
A EQUITY AND LIABILITIES			
1 Shareholder' funds			
(a) Share Capital	1,211	1,211	
(b) Reserves and surplus	23,880	19,550	
A Sub - total - Shareholder's funds	25,091	20,761	
2 Non-current liabilities			
(a) Long - term borrowings	7,664	8,070	
(b) Deferred tax liabilities (net)	3,101	2,751	
(c) Other long - term liabilities	1,151	1,003	
(d) Long - term provisions	-	286	
Total - Non - current liabilities	11,916	12,111	
3 Current liabilities			
(a) Short - term borrowings	26,560	21,496	
(b) Trade payables	15,018	13,189	
(c) Other current liabilities	4,418	3,024	
(d) Short - term provisions	1,971	1,389	
Total - current liabilities	47,967	39,100	
TOTAL - EQUITY AND LIABILITIES	84,974	71,972	
B ASSETS			
1 Non-current assets			
(a) Fixed assets (including CWP)	38,084	30,382	
(b) Non - current investments	462	513	
(c) Long - term loans and advances	704	256	
Total - Non - current assets	39,250	31,151	
2 Current assets			
(a) Inventories	12,673	14,092	
(b) Trade receivables	27,652	21,567	
(c) Cash and cash equivalents	440	288	
(d) Short - term loans and advances	2,220	1,960	
(e) Other non - current assets	2,739	2,913	
Total - current assets	45,724	40,821	
TOTAL - ASSETS	84,974	71,972	

Notes :

- The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 30th April, 2014
- The Board of Directors has recommended a Final Dividend of Rs.5.50/-per share on 1,21,08,550 Equity shares of Rs.10/- each fully paid-up for the Financial year 2013-14.
- Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.

For AARTI DRUGS LTD.


HARSHIT M. SAVLA
JT. MANAGING DIRECTOR



PARIKH JOSHI & KOTHARE (Regd.)

CHARTERED ACCOUNTANTS

49 / 2341, M.H.B. Colony, Gandhi Nagar, Bandra (East), Mumbai - 400 051.

☎ : +91 22 2651 5396 / 2645 1439 • Fax : +91 22 2645 5867 • E-mail : pjkbandra@yahoo.co.in • Website : www.pjkca.com

Auditor's Report On Quarterly and Annual Financial Results of Aarti Drugs Limited Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of Aarti Drugs Limited

We have audited the quarterly financial results of Aarti Drugs Limited for the quarter ended 31st March, 2014 and the annual results for the year ended 31st March, 2014 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results have been prepared on the basis of the interim financial statements and annual financial results have been prepared on the basis of the annual financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 read with the General Circular 15/2013 dated 13th September 2013 of the Ministry of Corporate Affairs in respect of section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the annual results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2014 as well as the annual results from 1st April, 2013 to 31st March, 2014.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of non promoter shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For PARIKH JOSHI & KOTHARE
CHARTERED ACCOUNTANTS



A handwritten signature in black ink, appearing to read "Tejas Parikh".

CA TEJAS PARIKH
PARTNER
M.No. 123215

Firm Registration No.: 107547W

Mumbai,

Dated: April 30, 2014